# US 2008/0187573 A1 · Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase b inhibitor component

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187573 A1
- Document ID: US20080187573A1
- Status: Published application
- Kind: A1
- Application number: 11/850,141
- Filed: 2007-09-05
- Published: 2008-08-07
- Earliest claimed: 1995-03-02
- Inventors: Francesca Mary Brewer; Edward Stuart Johnson; Anthony Clarke
- Web page: https://patentgrep.com/patent/US20080187573A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 31/136: having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 9/2095: {Tabletting processes}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A fast dispersing solid pharmaceutical composition having a monoamine oxidase B inhibitor as the only active ingredient is disclosed for the treatment of Parkinson's disease. The composition is formulated to promote absorption through the buccal, sublingual, pharyngeal and/or esophageal mucous membranes, such that at least 5% of the active ingredient is absorbed in one minute, as determined by a buccal absorption test.

## Claims

### Claim 1

A solid dispersible pharmaceutical composition for the treatment of a subject having Parkinson's disease consisting essentially of selegiline or a salt thereof or both selegiline and a salt thereof and one or more matrix forming agents, whereby selegiline is absorbed through the pre-gastric mucosa of the subject when the composition is placed into the oral cavity.

### Claim 2 (depends on 1)

The solid pharmaceutical composition of claim 1, which disintegrates within 10 seconds of being placed into the oral cavity.

### Claim 3 (depends on 2)

The composition of claim 2, which has been produced by a process comprising subliming solvent from the composition in a solid state.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the selegiline salt is a hydrochloric acid addition salt.

### Claim 5

A solid dispersible pharmaceutical composition for the treatment of a subject having Parkinson's disease consisting essentially of selegiline or a salt thereof or both selegiline and a salt thereof and one or more matrix forming agents, which composition disintegrates within 10 seconds of being placed into the oral cavity and whereby selegiline is absorbed through the pre-gastric mucosa of the subject when the composition is placed into the oral cavity.

### Claim 6

A solid dispersible pharmaceutical composition for the treatment of a subject having Parkinson's disease comprising as the sole active ingredient selegiline or a salt thereof or both selegiline and a salt thereof and a matrix forming agent, which composition disintegrates within 10 seconds of being placed into the oral cavity and whereby selegiline is absorbed through the pre-gastric mucosa of the subject when the composition is placed into the oral cavity.